

Transparency: Voluntary Disclosure of Payments to Healthcare Professionals and Healthcare Organizations

The Voluntary Framework on Disclosure was developed by Innovative Medicines Canada. As a partner in Canada's healthcare system, **Novartis Pharmaceuticals Canada Inc. (Novartis)** regularly collaborates with healthcare professionals (HCPs) and healthcare organizations (HCOs) to foster scientific exchange, for the ultimate benefit of patients. These collaborations are bound by local and international laws and regulated by Innovative Medicines Canada's Code of Ethical Practices.

Novartis' decision to publish our payments to HCPs and HCOs is voluntary and part of our overall commitment to greater transparency and high ethical standards in our business practices. **This commitment complements the significant investments we make in research and development across the country, which over the last 5 years, totaled approximately \$47 million.**

Novartis is proud of the relationships we have with Canadian HCPs, HCOs and other healthcare stakeholders. These relationships are critical to advancing scientific knowledge, education and quality of care for patients. By bringing greater transparency to our work, we hope to foster stronger understanding of our industry's collaborations across the healthcare sector, and enhance trust in Canada's healthcare system.

Payment information from January 1, 2021, to December 31, 2021, has been captured in aggregate form (one sum total) and presented below in three categories:

Accordion:



1. Fee for HCP Services

\$7 410 810.80*

One sum total of the company's payments to HCPs for services such as speaking and/or consulting. For further details: <http://innovativemedicines.ca/ethics/voluntary-disclosure-of-payments/> ^[1]



2. Funding to HCOs

\$1 715 353.75*

One sum total of the company's funding to HCOs, which supports efforts such as philanthropic (charitable), educational and/or scientific activities. For further details:
<http://innovativemedicines.ca/ethics/voluntary-disclosure-of-payments/> [1]

3. Sponsorship of HCP Travel

\$23 637.69*

One sum total of the company's funds provided to HCPs to support their travel to attend international congresses and/or global stand-alone meetings (scientific exchange meetings as per section 10.4 of the IMC Code of Ethical Practices). For further details:

<http://innovativemedicines.ca/ethics/voluntary-disclosure-of-payments/> [1]

Footnotes:

Note: While the Company makes every effort to present accurate and reliable information, the Company makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. The Company shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by Company or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and the Company is not responsible for the contents of or the availability of access to such websites.

*For clarity purposes only, please note the following:

- Applicable taxes may be excluded.
- The values provided may include certain related incidental expenses (such as, but not limited to reimbursement of mileage for travel).
- Transfer of Value (ToV) is captured according to the payment date and not necessarily the date on which the activity occurred. Therefore, some activities in 2020 are reported as ToVs in 2021, and some activities that occurred in 2021 will be reported in the 2022 report.

Source URL: <https://www.novartis.ca/en/about-us/corporate-responsibility/transparency-voluntary-disclosure-payments-healthcare>

Links

[1] <http://innovativemedicines.ca/ethics/voluntary-disclosure-of-payments/>